These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

213 related items for PubMed ID: 8320904

  • 1. Improvement of severe secondary hyperparathyroidism in dialysis patients by intravenous 1 alpha(OH) vitamin D3, oral CaCO3 and low dialysate calcium.
    Moriniere P, el Esper N, Viron B, Judith D, Bourgeon B, Farquet C, Gheerbrant J, Chapuy M, Van Orshoven A, Pamphile R.
    Kidney Int Suppl; 1993 Jun; 41():S121-4. PubMed ID: 8320904
    [Abstract] [Full Text] [Related]

  • 2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L.
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [Abstract] [Full Text] [Related]

  • 3. Prevention of hyperparathyroidism in patients on maintenance dialysis by intravenous 1-alpha-hydroxyvitamin D3 in association with Mg(OH)2 as sole phosphate binder. A randomized comparative study with the association CaCO3 +/- Mg(OH)2.
    Mornière P, Maurouard C, Boudailliez B, Westeel PF, Achard JM, Boitte F, el Esper N, Compagnon M, Maurel G, Bouillon R.
    Nephron; 1992 Nov; 60(2):154-63. PubMed ID: 1552999
    [Abstract] [Full Text] [Related]

  • 4. Long-term effects of intravenous 1 alpha (OH)D3 combined with CaCO3 and low-calcium dialysis on secondary hyperparathyroidism and biochemical bone markers in patients on chronic hemodialysis.
    Brandi L, Daugaard H, Nielsen PK, Jensen LT, Egsmose C, Olgaard K.
    Nephron; 1996 Nov; 74(1):89-103. PubMed ID: 8883025
    [Abstract] [Full Text] [Related]

  • 5. Use of alkaline calcium salts as phosphate binder in uremic patients.
    Fournier A, Morinière P, Ben Hamida F, el Esjer N, Shenovda M, Ghazali A, Bouzernidj M, Achard JM, Westeel PF.
    Kidney Int Suppl; 1992 Oct; 38():S50-61. PubMed ID: 1405382
    [Abstract] [Full Text] [Related]

  • 6. High-normal calcium (1.35 mmol/l) dialysate in patients on CAPD: efficient and safe long-term control of plasma calcium, phosphate, and parathyroid hormone.
    Bro S, Brandi L, Olgaard K.
    Nephrol Dial Transplant; 1996 Aug; 11(8):1586-91. PubMed ID: 8856216
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Long-term effects of intermittent oral alphacalcidol, calcium carbonate and low-calcium dialysis (1.25 mmol L-1) on secondary hyperparathyroidism in patients on continuous ambulatory peritoneal dialysis.
    Brandi L, Nielsen PK, Bro S, Daugaard H, Olgaard K.
    J Intern Med; 1998 Aug; 244(2):121-31. PubMed ID: 10095798
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Comparison of 1 alpha-OH-vitamin D3 and high doses of calcium carbonate for the control of hyperparathyroidism and hyperaluminemia in patients on maintenance dialysis.
    Morinière P, Fournier A, Leflon A, Hervé M, Sebert JL, Grégoire I, Bataille P, Guéris J.
    Nephron; 1985 Aug; 39(4):309-15. PubMed ID: 3982576
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Comparisons between oral pulse alfacalcidol therapy and daily therapy in maintenance hemodialysis patients with secondary hyperparathyroidism: a randomized, controlled, and multicenter study.
    Gu Y, Ding F, Chen N, Mei CL, Qian JQ, Wang XY, Shi W, Hou FF, Li XW, Wang M, Chen YP.
    Ren Fail; 2005 Aug; 27(2):205-12. PubMed ID: 15807187
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Long-term (6 months) cross-over comparison of calcium acetate with calcium carbonate as phosphate binder.
    Ben Hamida F, el Esper I, Compagnon M, Morinière P, Fournier A.
    Nephron; 1993 Aug; 63(3):258-62. PubMed ID: 8446261
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Calcium carbonate is an effective phosphate binder when dialysate calcium concentration is adjusted to control hypercalcemia.
    Mactier RA, Van Stone J, Cox A, Van Stone M, Twardowski Z.
    Clin Nephrol; 1987 Nov; 28(5):222-6. PubMed ID: 3427832
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.